Jennison Associates
CHRS icon

Jennison Associates’s Coherus Oncology CHRS Stock Holding History

Jennison Associates’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-26,840
Closed -$443K – 652
2018
Q3 		$443K Sell
26,840
-334
-1% -$5.92K ﹤0.01% 639
2018
Q2 		$380K Sell
27,174
-968
-3% -$13.9K ﹤0.01% 638
2018
Q1 		$311K Buy
+28,142
New +$308K ﹤0.01% 630
2017
Q3 		– Sell
-18,200
Closed -$261K – 659
2017
Q2 		$261K Buy
18,200
+69
+0.4% +$1.33K ﹤0.01% 631
2017
Q1 		$383K Sell
18,131
-764
-4% -$18.8K ﹤0.01% 621
2016
Q4 		$532K Buy
18,895
+4,470
+31% +$125K ﹤0.01% 671
2016
Q3 		$386K Buy
14,425
+932
+7% +$25.4K ﹤0.01% 620
2016
Q2 		$228K Buy
+13,493
New +$253K ﹤0.01% 629
2016
Q1 		– Sell
-367,021
Closed -$8.43M – 619
2015
Q4 		$8.43M Buy
367,021
+11,023
+3% +$284K 0.01% 487
2015
Q3 		$7.13M Buy
355,998
+2,635
+0.7% +$80.2K 0.01% 524
2015
Q2 		$10.2M Buy
+353,363
New +$8.93M 0.01% 514

Other funds holding CHRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates's CHRS Position: Q4 2018 in Review

Jennison Associates sold out of Coherus Oncology (CHRS) in Q4 2018, closing a stake of 26,840 shares — an estimated $443K sold.

Jennison Associates first reported a position in CHRS in Q2 2015 and held it in 11 quarters. The position peaked at $10.2M in Q2 2015. 111 funds tracked by Wall St. Rank hold CHRS as of Q4 2018.

  • Jennison Associates reported no remaining Coherus Oncology position as of Q4 2018 after selling out during the quarter.
  • Jennison Associates sold 26,840 Coherus Oncology shares in Q4 2018, an estimated $443K.
  • Jennison Associates first reported a position in Coherus Oncology in Q2 2015 and held it in 11 quarters.
  • Jennison Associates's Coherus Oncology position peaked at $10.2M in Q2 2015.
  • 111 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2018.

Based on Jennison Associates's 13F filing for Q4 2018, filed 6 Feb 2019.